MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • CytRx Corp. (CYTR) Presenting At Oppenheimer 24th Annual Healthcare Conference; Receives Positive Mention On StreetInsider.com 0 comments
    Dec 4, 2013 2:46 PM | about stocks: CYTR

    CytRx, a biopharmaceutical research and development company specializing in oncology treatments, reported today it will be at the Oppenheimer 24th annual Healthcare Conference, being held next week in New York City. The conference is being held Tuesday, December 10 through Wednesday, December 11, 2013, at the Crowne Plaza Hotel. The company's President and CEO, Steven A. Kriegsman, and Executive Vice President and Chief Medical Officer, Dr. Daniel Levitt, will be providing a corporate update on Wednesday, December 11, 2013 at 4:30 PM EST.

    The presentation will be webcast, available at: www.cytrx.com/investors/presentations

    The Oppenheimer conference is an event in which management teams from over 100 companies present up-to-date information on their companies and their performances. Presenters cover a wide range of public and private healthcare companies spanning over all of the healthcare industry, including: bio & specialty pharmaceuticals; biotechnology; medical devices; healthcare facilities; life science tools and diagnostics; healthcare information technology and distribution, and healthcare providers and servicers.

    CytRx's oncology pipeline is currently focused on the clinical development of aldoxorubicin, its improved version of the widely-used chemotherapeutic treatment doxorubicin.

    Information about CytRx's Aldoxorubicin Clinical Trial Progress

    CytRx is conducting a global Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and has completed a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx plans to initiate under a special protocol assessment a potential pivotal Phase 3 global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx also has initiated a Phase 2 clinical trial with aldoxorubicin in patients with late-stage glioblastoma (brain cancer) and plans to initiate a Phase 2 clinical trial for AIDS-related Kaposi's sarcoma.

    Positive Notes

    In an article on StreetInsider.com, analyst Ram Selvaraju noted CytRx's positive indicators as a stock buy, saying, "Over the course of the past several weeks, CytRx has reported several significant developments. The firm previously reported positive response data from a Phase 2b trial assessing aldoxorubicin versus doxorubicin as front-line therapy in soft tissue sarcoma (NYSEMKT:STS)."

    The full article can be accessed at: www.streetinsider.com/Analyst+Comments/P....html

    For more information on CytRx, visit: cytrx.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CYTR
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.